BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 19573980)

  • 1. A proposal for reclassification of the Fuhrman grading system in patients with clear cell renal cell carcinoma.
    Sun M; Lughezzani G; Jeldres C; Isbarn H; Shariat SF; Arjane P; Widmer H; Pharand D; Latour M; Perrotte P; Patard JJ; Karakiewicz PI
    Eur Urol; 2009 Nov; 56(5):775-81. PubMed ID: 19573980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of simplified versions of the Fuhrman nuclear grading system in clinical practice requires the agreement of a multidisciplinary panel of experts.
    Ficarra V; Novara G; Martignoni G
    Eur Urol; 2009 Nov; 56(5):782-4; discussion 784-5. PubMed ID: 19660853
    [No Abstract]   [Full Text] [Related]  

  • 3. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Maffei N; Brunelli M; Novara G; Zanolla L; Pea M; Artibani W
    Cancer; 2005 Jan; 103(1):68-75. PubMed ID: 15573369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Grading of clear cell renal cell carcinoma should be based on nucleolar prominence.
    Delahunt B; Sika-Paotonu D; Bethwaite PB; William Jordan T; Magi-Galluzzi C; Zhou M; Samaratunga H; Srigley JR
    Am J Surg Pathol; 2011 Aug; 35(8):1134-9. PubMed ID: 21716085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.
    Isbarn H; Patard JJ; Lughezzani G; Rioux-Leclercq N; Crépel M; Cindolo L; de la Taille A; Zini L; Villers A; Shariat SF; Bertini R; Karakiewicz PI
    Urology; 2010 Jun; 75(6):1378-84. PubMed ID: 19781745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of lymph node invasion and sarcomatoid differentiation on the survival of patients with locally advanced renal cell carcinoma.
    Rodríguez-Covarrubias F; Castillejos-Molina R; Sotomayor M; Méndez-Probst CE; Gómez-Alvarado MO; Uribe-Uribe N; Gabilondo F; Feria-Bernal G
    Urol Int; 2010; 85(1):23-9. PubMed ID: 20693824
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
    Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
    Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: Assessment of 241 patients with > 15-year follow-up.
    Lang H; Lindner V; de Fromont M; Molinié V; Letourneux H; Meyer N; Martin M; Jacqmin D
    Cancer; 2005 Feb; 103(3):625-9. PubMed ID: 15611969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Critical analysis of a simplified Fuhrman grading scheme for prediction of cancer specific mortality in patients with clear cell renal cell carcinoma--Impact on prognosis.
    Becker A; Hickmann D; Hansen J; Meyer C; Rink M; Schmid M; Eichelberg C; Strini K; Chromecki T; Jesche J; Regier M; Randazzo M; Tilki D; Ahyai S; Dahlem R; Fisch M; Zigeuner R; Chun FK
    Eur J Surg Oncol; 2016 Mar; 42(3):419-25. PubMed ID: 26520403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma with venous extension.
    Martínez-Salamanca JI; Huang WC; Millán I; Bertini R; Bianco FJ; Carballido JA; Ciancio G; Hernández C; Herranz F; Haferkamp A; Hohenfellner M; Hu B; Koppie T; Martínez-Ballesteros C; Montorsi F; Palou J; Pontes JE; Russo P; Terrone C; Villavicencio H; Volpe A; Libertino JA;
    Eur Urol; 2011 Jan; 59(1):120-7. PubMed ID: 20980095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the UCLA Integrated Staging System and the Leibovich score in survival prediction for patients with nonmetastatic clear cell renal cell carcinoma.
    Tan MH; Kanesvaran R; Li H; Tan HL; Tan PH; Wong CF; Chia KS; Teh BT; Yuen J; Chong TW
    Urology; 2010 Jun; 75(6):1365-1370; 1370.e1-3. PubMed ID: 20022084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma.
    Adamy A; Chong KT; Chade D; Costaras J; Russo G; Kaag MG; Bernstein M; Motzer RJ; Russo P
    J Urol; 2011 Feb; 185(2):433-8. PubMed ID: 21167521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: single-center experience.
    Ciancio G; Manoharan M; Katkoori D; De Los Santos R; Soloway MS
    Eur Urol; 2010 Apr; 57(4):667-72. PubMed ID: 19560258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study.
    Cindolo L; Patard JJ; Chiodini P; Schips L; Ficarra V; Tostain J; de La Taille A; Altieri V; Lobel B; Zigeuner RE; Artibani W; Guillé F; Abbou CC; Salzano L; Gallo C
    Cancer; 2005 Oct; 104(7):1362-71. PubMed ID: 16116599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathological prognostic indicators in renal cell carcinoma].
    Rey Rey J; León Ramírez D; López García S; Fernández Vázquez P; Benavente Delgado J; Ojea Calvo A
    Actas Urol Esp; 2010 Jan; 34(1):71-7. PubMed ID: 20223135
    [TBL] [Abstract][Full Text] [Related]  

  • 19. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.